Pathios Therapeutics
Pathios is a clinical-stage oncology and immunology company that targets the acid-sensing GPCR, GPR65, as a unique and genetically-validated immune cell receptor with the potential to revolutionise oncology treatment across multiple solid tumor types
Using human genetics to transform cancer outcomes
Pathios is exploiting a proprietary understanding of the human genetics and functional immunology of GPR65 to bring about a revolutionary new approach to treating cancer
Targeting GPR65
Pathios are the only company addressing the root cause of dysfunctional immune cells within the TME by inhibiting GPR65
Clinical-stage company
Pathios is the first company in the world to advance a GPR65 antagonist into cancer patients with its lead asset, PTT-4256
